Bristol-Meyers Squibb

Industry-wide accelerated approval review yields four withdrawals
Industry-wide accelerated approval review yields four withdrawals
RAPS.org
FDA
Bristol-Meyers Squibb
Roche
Merck
AstraZeneca
accelerated approvals
Flag link:
Esmo 2020 preview – late-breaking immunotherapy
Esmo 2020 preview – late-breaking immunotherapy
EP Vantage
ESMO
immunotherapy
Big Pharma
Merck
Bristol-Meyers Squibb
cancer
Immunomedics
Roche
Flag link:
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Xconomy
Bristol-Meyers Squibb
Dragonfly Therapeutics
multiple sclerosis
MS
neuroinflammation
Flag link:
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
Flag link:
FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatment of adults in remission with AML
FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatment of adults in remission with AML
Pharmaceutical Business Review
Bristol-Meyers Squibb
FDA
CC-486
AML
acute myeloid leukemia
Flag link:
Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb
Motion denied: Gilead still on the hook for $1.5B in damages over CAR-T patent dispute with Bristol Myers Squibb
Endpoints
Gilead Sciences
CAR-T
Bristol-Meyers Squibb
Juno Therapeutics
patents
Flag link:
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
Flag link:
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Flag link: